We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

21 hedge funds and large institutions have $4.51M invested in Biolase, Inc. in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

11% more funds holding

Funds holding: 19 → 21 (+2)

31% less capital invested

Capital invested by funds: $6.54M → $4.51M (-$2.03M)

Holders
21
Holders Change
+2
Holders Change %
+10.53%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
+$37.3K
2
Renaissance Technologies
Renaissance Technologies
New York
+$24.9K
3
WVP
Worth Venture Partners
New Jersey
+$24.9K
4
DAS
Dynamic Advisor Solutions
Arizona
+$10.9K
5
CFGS
Concourse Financial Group Securities
Alabama
+$9.32K

Top Sellers

Rank Fund Capital Flow
1
TMC
Trellus Management Company
Florida
-$9K
2
Morgan Stanley
Morgan Stanley
New York
-$1.55K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$1.55K
Name Holding Trade Value Shares
Change 		Change in
Stake
OIM
1
Oracle Investment Management
Connecticut
$1.94M – – –
ACM
2
Archon Capital Management
Washington
$1M – – –
PCM
3
Perkins Capital Management
Minnesota
$518K +$37.3K +24 +5%
Vanguard Group
4
Vanguard Group
Pennsylvania
$365K -$1.55K -1 -0.3%
WPC
5
White Pine Capital
Minnesota
$241K +$7.77K +5 +2%
WVP
6
Worth Venture Partners
New Jersey
$212K +$24.9K +16 +8%
BlackRock
7
BlackRock
New York
$116K +$6.21K +4 +3%
Renaissance Technologies
8
Renaissance Technologies
New York
$24K +$24.9K +16 +178%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$18K – – –
Northern Trust
10
Northern Trust
Illinois
$14K – – –
California Public Employees Retirement System
11
California Public Employees Retirement System
California
$13K – – –
MCM
12
Marathon Capital Management
Maryland
$7K +$3.11K +2 +33%
DAS
13
Dynamic Advisor Solutions
Arizona
$7K +$10.9K +7 New
CFGS
14
Concourse Financial Group Securities
Alabama
$6K +$9.32K +6 New
RJFSA
15
Raymond James Financial Services Advisors
Florida
$4K – – –
WSC
16
Wellington Shields & Co
New York
$4K – – –
Victory Capital Management
17
Victory Capital Management
Texas
$4K +$4.66K +3 New
UBS Group
18
UBS Group
Switzerland
$4K +$6.21K +4 New
TFO
19
Tarbox Family Office
California
$3K – – –
Morgan Stanley
20
Morgan Stanley
New York
$2K -$1.55K -1 -33%
IA
21
IFP Advisors
Florida
$2K – – –
APA
22
American Portfolios Advisors
New York
$153 – – –
TMC
23
Trellus Management Company
Florida
– -$9K -7 Closed

BIOL Hedge Fund Activity: Q1 2020 in Review

21 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2020, worth a combined $4.51M — down 31% from $6.54M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BIOL positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Perkins Capital Management, adding an estimated $37.3K. The largest seller was Trellus Management Company, exiting entirely with an estimated $9K sold.

  • 21 institutional investors held Biolase, Inc. (BIOL) as of Q1 2020, up from 19 in Q4 2019.
  • Funds reported $4.51M of Biolase, Inc. stock for Q1 2020, down 31% quarter-over-quarter.
  • 4 funds opened new Biolase, Inc. positions in Q1 2020 and 1 closed out, a net change of +3 holders.
  • The largest Biolase, Inc. buyer in Q1 2020 was Perkins Capital Management, an estimated $37.3K added.
  • The largest Biolase, Inc. seller in Q1 2020 was Trellus Management Company, an estimated $9K sold.

Based on aggregated 13F filings for Q1 2020.